1477 — Ocumension Therapeutics Share News
0.000.00%
Last trade - 00:00- HK$3.71bn
- HK$3.43bn
- CNY804.35m
Brief: Ocumension Therapeutics Says OT-502 Approved By NMPA To Conduct A Phase III Clinical Trial In China
Brief: Ocumension Therapeutics Says Novartis Agrees To Transfer To Ocumension Hong Kong Transferred Assets In Territory
Brief: Ocumension Therapeutics Says OT-502 Approved For Real World Study In Hainan Boao
Brief: Ocumension Therapeutics Says CDE Approval Received For A Phase Iii Clinical Trial Of Ot-101
Brief: Ocumension Therapeutics Says Phase III Clinical Trial Of OT-502 Approved In China
Brief: Ocumension Therapeutics Says Hainan Medical Product Administration Granted Approval To Group's OT-502
Brief: Nicox To Get USD 2 Mln Advance Payment From Ocumension Under Zerviate Agreement
Brief: Capital Group Companies Inc Bought 3.8 Mln Shares In Ocumension Therapeutics On June 10 - HKEX Filing
HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan
Brief: Ocumension Therapeutics Says Morgan Stanley & Co To Place 8.6 Million Existing Shares Of Co
Brief: Ocumension Therapeutics Announces Clinical Trial Authorization For A Phase Iii Clinical Trial Of Ot-101
Brief: Ocumension Therapeutics Says Ind Application Received For A Phase Iii Clinical Trial Of Ot-101 In China
Brief: Ocumension Therapeutics' Unit And Alimera Entered Into Exclusive License Agreement
Alimera Sciences: Rises on license agreement, investment from Ocumension Therapeutics
Brief: Ocumension Therapeutics Says New Drug Application For Ot-401 (Yutiq) Has Been Accepted By NMPA Of PRC
Brief: Ocumension Therapeutics Says Total Revenue Was Rmb13.1 Mln For Year
Brief: Ocumension Therapeutics Announces Inclusion In HK Stock Connect List Under Shenzhen-HK Stock Connect
Brief: Ocumension Therapeutics Says 2nd Phase III Clinical Trial Of Ot-301 Approved In China By NMPA
Brief: Ocumension Therapeutics Announces IND Approval For Multi-Regional Phase Iii Clinical Trial In U.S.